Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06750432 | PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD) | PHASE1 | ACTIVE NOT_RECRUITING | 144 | — | — | Dec 13, 2024 | Dec 1, 2026 | Dec 24, 2025 | 22 | United States |
Number and severity of adverse events
Mean change in plasma p-tau217 in response to repeat intravenous infusions of PMN310
| Arm | Type | Description |
|---|---|---|
| Cohort 1 PMN310 350 mg or placebo | EXPERIMENTAL | PMN310 350 mg or placebo administered as a 60-minute infusion. |
| Cohort 2 PMN310 700 mg or placebo | EXPERIMENTAL | PMN310 700 mg or placebo administered as a 60-minute infusion. |
| Cohort 3 PMN310 1400 mg or placebo | EXPERIMENTAL | PMN310 1400 mg or placebo administered as a 60-minute infusion. |
| Name | Type | Description |
|---|---|---|
| PMN310 | DRUG | A humanized immunoglobulin G1 (IgG1) monoclonal antibody |
| Placebo | DRUG | 0.9% NaCl 100 mL |
Inclusion Criteria: 1. Patient and caregiver provide written informed consent. 2. Ambulatory male or female ≥ 50 years of age with adequate visual and auditory abilities to perform the cognitive and functional assessments in the opinion of the Investigator. 3. Meets all of the following clinical cr...